Loading the page…
Nasdaq 100
VRTX
Vertex Pharmaceuticals Incorporated, Health Care
$558.88
+3.50% on the day
Close of Fri, Oct 30, 2026
+17.1% over 3M
2026-07-312026-09-162026-10-30
Market cap$141.7B
Last close$558.88
Day move+3.50%
Nasdaq 100
Vertex Pharmaceuticals Incorporated, Health Care
$558.88
+3.50% on the day
Close of Fri, Oct 30, 2026
| Quarter ending | Jun 2026 | Mar 2026 | Dec 2025* | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024* | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.3B | $3.0B | $3.2B | $3.1B | $3.0B | $2.8B | $2.9B | $2.8B |
| Gross margin | 85.3% | 86.8% | 85.4% | 86.5% | 86.3% | 86.9% | 85.5% | 85.8% |
| Operating margin | 37.4% | 38.1% | 37.8% | 38.6% | 38.8% | 22.7% | 35.2% | 40.3% |
| Net margin | 33.0% | 34.5% | 37.3% | 35.2% | 34.8% | 23.3% | 31.4% | 37.7% |
| EPS, diluted | $4.31 | $4.02 | $4.64 | $4.20 | $3.99 | $2.49 | $3.62 | $4.01 |
From the company's SEC filings, newest first. * A fiscal fourth quarter: the year's 10-K less its first three quarters.
The same ranks the builder's sliders blend. Small and Wild are Big and Calm turned over.
| Measure | VRTX | Higher than |
|---|---|---|
| Earnings yield (earnings ÷ price) | 3.1% | 55% |
| Book yield (book value ÷ price) | 14.3% | 64% |
| Free cash flow yield | 2.3% | 49% |
| Buyback yield | 1.4% | 62% |
| Revenue growth, a year | 8.9% | 38% |
| EPS growth, a year | 836.5% | 97% |
| Return on equity | 21.8% | 49% |
| Return on assets | 16.1% | 70% |
| Net margin | 35.0% |
Research
Figures from SEC filings and daily closes; results dates and headlines from Yahoo Finance and Nasdaq; insider trades from SEC Form 4. For learning, not investment advice.
| 91% |
| Liabilities ÷ assets | 26.2% | 14% |
|---|
| Past year, skipping last month | 21.5% | 60% |
|---|
| Past 6 months, skipping last month | 19.5% | 75% |
|---|
| Volatility, a year's worth | 28.6% | 28% |
|---|
"Higher than" is the share of the 100 with a lower figure. Financial figures from SEC filings, market figures from daily closes. Dividend yield and beta are under Valuation below.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.
From Yahoo Finance, vrtx.com
Is Vertex Pharmaceuticals (VRTX) Fully Priced Following Its Kidney Data Update?Simply Wall St., 30m ago
What Just Happened To Alnylam Stock?Trefis, Oct 30
3 large-cap stocks with solid fundamentalsStockStory, Oct 30Is 50% Crash Risk For Iovance Stock Real?Trefis, Oct 30Why Did Insmed Stock Jump?Trefis, Oct 30Headlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
Picked by YouTube search, not by us. Someone else's view, not advice.
Is Vertex Pharmaceuticals (VRTX) Fully Priced Following Its Kidney Data Update?Simply Wall St., 30m agoWhat Just Happened To Alnylam Stock?Trefis, Oct 303 large-cap stocks with solid fundamentalsStockStory, Oct 30Is 50% Crash Risk For Iovance Stock Real?Trefis, Oct 30Why Did Insmed Stock Jump?Trefis, Oct 30
What iShares Biotechnology ETF (IBB) Bought: Gilead Leads on Oct. 28GuruFocus.com, Oct 30Vertex Pharmaceuticals Says UK Approves Casgevy for Children Aged 5 and OlderMT Newswires, Oct 30Can Iovance Stock Fall 50%?Trefis, Oct 29
Biogen Crushes Earnings Estimates. As Old Blockbusters Fade, New Bets Pick Up the Slack.Barrons.com, Oct 28
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks, Oct 28Headlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
Open-market buys and sells are the ones that say something; awards, exercises and tax withholding are routine.
Every transaction, in AdvancedSEC Form 4, public domain. The latest 40 of 110 Form 4 filings from the last 12 months are counted. A sale filled at several prices is one line at its average price. All Form 4s on EDGAR
Open-market buys and sells are the ones that say something; awards, exercises and tax withholding are routine.
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 20, 2026 | Brennan Daniel J.Director | Award | +795 | $503.47 | $400K | Form 4 ↗ |
| Oct 15, 2026 | Sachs Bruce IDirector | AwardDeferred Stock Units | +93 | $512.44 | $47.5K | Form 4 ↗ |
| Oct 15, 2026 | Garber Alan MDirector | AwardDeferred Stock Units | +29 | $512.44 | $15K | Form 4 ↗ |
| Sep 8, 2026 | van Grunsven JasperEVP, CP and NPPO | Award | +8,682 | — | — | Form 4 ↗ |
| Aug 28, 2026 | Ambrose KristenSVP & CAO | Award | +5,000 | — | — | Form 4 ↗ |
| Aug 27, 2026 | Sachs Bruce IDirector | Gift | −6,000 | — | — | Form 4 ↗ |
| Jul 21, 2026 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Award | +8,251 | — | — | Form 4 ↗ |
| Jul 21, 2026 | Sachdev AmitEVP Chief Patient & Ext Af Off | Award | +8,251 | — | — | Form 4 ↗ |
| Jul 15, 2026 | Sachs Bruce IDirector | AwardDeferred Stock Units | +100 | $475.28 | $47.5K | Form 4 ↗ |
| Jul 15, 2026 | Garber Alan MDirector | AwardDeferred Stock Units | +32 | $475.28 | $15K | Form 4 ↗ |
| Jul 2, 2026 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Sold on the market10b5-1 plan | −1,500 | $524.99 | $787K | Form 4 ↗ |
| Jul 2, 2026 | McKechnie DuncanEVP, Chief Commercial Officer | Sold on the market10b5-1 plan | −1,541 | $519.00 | $800K | Form 4 ↗ |
| Jul 1, 2026 | Liu JoyEVP and Chief Legal Officer | Sold on the market10b5-1 plan | −828 | $502.71 | $416K | Form 4 ↗ |
| Jun 26, 2026 | Bozic CarmenEVP and CMO | Sold on the market10b5-1 plan | −596 | $482.50 | $288K | Form 4 ↗ |
| Jun 18, 2026 | Bozic CarmenEVP and CMO | Sold on the market10b5-1 plan | −1,020 | $462.17 | $471K | Form 4 ↗ |
| Jun 15, 2026 | Bozic CarmenEVP and CMO | Sold on the market10b5-1 plan | −4,062 | $450.00 | $1.8M | Form 4 ↗ |
| Jun 5, 2026 | Bozic CarmenEVP and CMO | Sold on the market10b5-1 plan | −1,745 | $450.00 | $785K | Form 4 ↗ |
| Jun 1, 2026 | Liu JoyEVP and Chief Legal Officer | Sold on the market10b5-1 plan | −828 | $439.91 | $364K | Form 4 ↗ |
| May 29, 2026 | Bozic CarmenEVP and CMO | Sold on the market10b5-1 plan | −1,974 | $450.00 | $888K | Form 4 ↗ |
| May 15, 2026 | Bunnage Mark E.EVP, Chief Scientific Officer | Sold on the market10b5-1 plan | −33 | $453.45 | $15K | Form 4 ↗ |
| May 15, 2026 | Bozic CarmenEVP and CMO | Sold on the market10b5-1 plan | −1,354 | $453.45 | $614K | Form 4 ↗ |
| May 12, 2026 | Bozic CarmenEVP and CMO | Sold on the market10b5-1 plan | −6,988 | $450.00 | $3.1M | Form 4 ↗ |
| May 4, 2026 | Bhatia Sangeeta N.Director | Sold on the market10b5-1 plan | −318 | $423.73 | $135K | Form 4 ↗ |
| May 1, 2026 | Upadhyay SuketuDirector | Returned to the company | −796 | — | — | Form 4 ↗ |
| May 1, 2026 | Upadhyay SuketuDirector | AwardStock Option (Right to Buy) | +2,866 | — | — | Form 4 ↗ |
| May 1, 2026 | Upadhyay SuketuDirector | AwardDeferred Stock Units | +796 | — | — | Form 4 ↗ |
| May 1, 2026 | Thornberry NancyDirector | Award | +472 | — | — | Form 4 ↗ |
| May 1, 2026 | Thornberry NancyDirector | Returned to the company | −398 | — | — | Form 4 ↗ |
| May 1, 2026 | Thornberry NancyDirector | AwardStock Option (Right to Buy) | +1,433 | — | — | Form 4 ↗ |
| May 1, 2026 | Thornberry NancyDirector | AwardDeferred Stock Units | +398 | — | — | Form 4 ↗ |
| May 1, 2026 | Schneider JenniferDirector | Award | +472 | — | — | Form 4 ↗ |
| May 1, 2026 | Schneider JenniferDirector | Returned to the company | −796 | — | — | Form 4 ↗ |
| May 1, 2026 | Schneider JenniferDirector | AwardStock Option (Right to Buy) | +1,433 | — | — | Form 4 ↗ |
| May 1, 2026 | Schneider JenniferDirector | AwardDeferred Stock Units | +796 | — | — | Form 4 ↗ |
| May 1, 2026 | Sachs Bruce IDirector | AwardStock Option (Right to Buy) | +2,866 | — | — | Form 4 ↗ |
| May 1, 2026 | Mckenzie DianaDirector | Award | +943 | — | — | Form 4 ↗ |
| May 1, 2026 | Mckenzie DianaDirector | Returned to the company | −796 | — | — | Form 4 ↗ |
| May 1, 2026 | Mckenzie DianaDirector | AwardDeferred Stock Units | +796 | — | — | Form 4 ↗ |
| May 1, 2026 | Liu JoyEVP and Chief Legal Officer | Sold on the market10b5-1 plan | −1,104 | $425.02 | $469K | Form 4 ↗ |
| May 1, 2026 | Lagarde MichelDirector | AwardStock Option (Right to Buy) | +2,866 | — | — | Form 4 ↗ |
| May 1, 2026 | Garber Alan MDirector | Award | +472 | — | — | Form 4 ↗ |
| May 1, 2026 | Garber Alan MDirector | AwardStock Option (Right to Buy) | +1,433 | — | — | Form 4 ↗ |
| May 1, 2026 | Carney LloydDirector | AwardStock Option (Right to Buy) | +2,866 | — | — | Form 4 ↗ |
| May 1, 2026 | Bhatia Sangeeta N.Director | Award | +943 | — | — | Form 4 ↗ |
| Apr 15, 2026 | Upadhyay SuketuDirector | AwardDeferred Stock Units | +81 | $442.50 | $35.6K | Form 4 ↗ |
| Apr 15, 2026 | Sachs Bruce IDirector | AwardDeferred Stock Units | +107 | $442.50 | $47.5K | Form 4 ↗ |
| Apr 15, 2026 | Garber Alan MDirector | AwardDeferred Stock Units | +34 | $442.50 | $15K | Form 4 ↗ |
| Apr 1, 2026 | Liu JoyEVP and Chief Legal Officer | Sold on the market10b5-1 plan | −978 | $449.17 | $439K | Form 4 ↗ |
| Mar 27, 2026 | Bozic CarmenEVP and CMO | Sold on the market10b5-1 plan | −2,329 | $450.95 | $1.1M | Form 4 ↗ |
| Mar 13, 2026 | Bozic CarmenEVP and CMO | Sold on the market10b5-1 plan | −2,329 | $481.79 | $1.1M | Form 4 ↗ |
| Mar 11, 2026 | McKechnie DuncanEVP, Chief Commercial Officer | Sold on the market10b5-1 plan | −2,633 | $498.42 | $1.3M | Form 4 ↗ |
| Mar 4, 2026 | McKechnie DuncanEVP, Chief Commercial Officer | Sold on the market10b5-1 plan | −2,437 | $475.30 | $1.2M | Form 4 ↗ |
SEC Form 4, public domain. The latest 40 of 110 Form 4 filings from the last 12 months are counted. A sale filled at several prices is one line at its average price. All Form 4s on EDGAR
Beat the forecast in 4 of the last 4 quarters.
The stock's move is from the close before the report to the close after it.